Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27982785 | 0.86 | PRSS1 (0.59) | PRSS1PRSS2PRSS3CNR2SMYD3 | |
| SCHEMBL1002846 | 0.84 | CES2 (0.53) | CES2CES1VNN1KMT2AACHE | |
| SCHEMBL7046114 | 0.80 | L3MBTL1 (0.65) | PRSS1PRSS2PRSS3CNR2SMYD3 | |
| SCHEMBL7967901 | 0.80 | CES2 (0.73) | CES2CES1VNN1KMT2AHSD17B14 | |
| SCHEMBL4710159 | 0.79 | MAOB (0.44) | CES2CES1VNN1KMT2A | |
| SCHEMBL13664920 | 0.79 | CES2 (0.47) | CES2CES1VNN1ACHEHSD17B14 | |
| SCHEMBL332679 | 0.78 | ATM (0.61) | CES2CES1VNN1KMT2AACHE | |
| SCHEMBL14409543 | 0.77 | VNN1 (0.55) | VNN1PRSS1PRSS2PRSS3CNR2 | |
| SCHEMBL13664921 | 0.77 | CES2 (0.53) | CES2CES1VNN1KMT2AHSD17B14 | |
| SCHEMBL5937441 | 0.77 | CYP11B1 (0.57) | CES1CNR2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | CES2 2405/4885CES1 1844/4885VNN1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.